Group Says Four Nigerian Drug Manufacturers Met WHO’s Requirements | Independent Newspapers Limited
Newsletter subscribe

Business, Industry

Group Says Four Nigerian Drug Manufacturers Met WHO’s Requirements

Posted: Sep 11, 2015 at 12:05 am   /   by   /   comments (0)

The Pharmaceutical Manufacturers Group of the Manufacturers Association of Nigeria (PMGMAN) has said that four Nigerian drug manufacturers had met the World Health Organisation (WHO)’s requirements for good manufacturing practice.

The Chairman of the association, Mr. Okey Akpa, disclosed this at the opening ceremony of a three-day Nigeria Pharma Manufacturers Expo 2015 with the Theme: “The Nigerian Pharmaceutical Manufacturing Industry and International Competitiveness” in Lagos.

Akpa, who listed the manufacturers as Swiss Pharma Nigeria Limited, CHI Pharmaceutical Limited, Evans Medical Plc and May & Baker Nigeria Limited, noted that many pharmaceutical manufacturers have also complied with the requirements of International Standards Organisation.

He said: “Nigeria Pharmaceutical Manufacturers have also developed, manufactured and registered products for the UN Commission and life-saving commodities for women’s and children’s health.”

Akpa, who argued that many international pharmaceutical companies were not interested in research and development investments for conditions such as sickle cell anaemia and malaria which were peculiar to African continent, said, “Nigeria is currently the biggest pharmaceutical manufacturing country in West Africa.

“It accounts for more than 65 percent of the local manufacture of medicines relevant to the people and diseases of our nation and region.

“They are anti-malaria medicines, anti-retroviral medicines for HIV/AIDS, herbal medicines and medicines for sickle cell diseases and many others.”

He noted that many manufacturers in the country had also processed the Expression of Interest (EOI) with the WHO for pre-qualification of products.

“Manufacturers processing WHO prequalification have invested over 50 million dollars in the last five years,” he said.

He urged the Federal Government to give the drug manufacturers some incentives such as tax holidays to support the extra investment for quality upgrades and new factories.

He appealed to the government to initiate policies to support pharmaceutical innovators, international suppliers and partners to sustain the gains made so far by the pharmaceutical industry.